Skip to main content

Acadia Value Stock - Dividend - Research Selection

Acadia Pharmaceuticals

ISIN: US0042251084, WKN: 603035

Market price date: 17.05.2022
Market price: 17,05 USD


Acadia Pharmaceuticals Fundamental data and company key figures of the share

Annual reports in USD
Key figures 15-03-2022
Cash flow
Net operating cash flow -125.660.000
Capital Expenditures -1.122.000
Free cash flow -126.782.000
Balance sheet
Total Equity 540.894.000
Liabilities & Shareholders equity 700.122.000
Income statement
Net income -167.870.000
Eps (diluted) -1,049
Diluted shares outstanding 160.663.000
Net sales/revenue 484.145.000

Fundamental ratios calculated on: 17-05-2022

Ratios
Key figures 17-05-2022
Cash flow
P/C -21,80
   
P/FC -21,61
Balance sheet
ROI-23,98
ROE77,26
Income statement
P/E-16,25
Div. Yield0,00%
P/B5,06
P/S5,66


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolACAD
Market Capitalization2.739.304.192,00 USD
CountryUnited States
IndicesNASDAQ Comp.,Russell 3000
SectorsBiotechnology
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internetwww.acadia-pharm.com


Description of the company

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The Company has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a first-in-class treatment for Parkinson's disease psychosis. It holds worldwide commercialization rights to pimavanserin. In addition, the Company has a product candidate in Phase II development for chronic pains and a product candidate in Phase I development for glaucoma, both in collaboration with Allergan, Inc., and a product candidate in Phase I development for schizophrenia in collaboration with Meiji Seika Pharma Co., Ltd. The Company's clinical-stage product candidates include Pimavanserin, Alpha Adrenergic Agonists, Muscarinic Agonist and AM-831.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.acadia-pharm.com


NEWS


SEC filings reveal massive selling in media names, including Disney and Comcast

2022-05-16
Leslie Picker joins the 'Halftime Report' to discuss what to expect from the SEC 13-F filings.

Cable companies to offer effectively free internet to low-income homes

2022-05-09
The news means that tens of millions of households could receive high-speed internet at no cost, according to the White House.

Acadia (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates

2022-05-05
Acadia (ACAD) posts wider-than-expected loss for the first quarter of 2022 while revenues miss estimates.

Interesting ACAD Put And Call Options For June 24th

2022-05-05
Staff article entitled Interesting ACAD Put And Call Options For June 24th, about stock options, from Stock Options Channel.

ACADIA PHARMACEUTICALS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTSOF OPERATIONS (form 10-Q)

2022-05-05
The following discussion and analysis of our consolidated financial conditionand results of operations should be read in conjunction with our unauditedcondensed consolidated financial statements... | May 5, 2022

ABC Boosts EPS Outlook, ADPT Sees 20-26% Revenue Growth, ANAB To Report HARP Data In Q3

2022-05-05
(RTTNews) - The following are some of biotech companies that provided an update on their pipeline progress and reported quarterly results.

Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates

2022-05-04
Acadia (ACAD) delivered earnings and revenue surprises of -42.86% and 6.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results

2022-05-04
SAN DIEGO, May 04, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2022.

Acadia: Q1 Earnings Snapshot

2022-05-04
SAN DIEGO _ Acadia Pharmaceuticals Inc. on Wednesday reported a loss of $113.1 million in its first quarter. The San Diego-based company said it had a loss of 70 cents per share. ... | May 4, 2022

ACADIA PHARMACEUTICALS INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

2022-05-04
Item 2.02 Results of Operations and Financial Condition.On May 4, 2022, Acadia Pharmaceuticals Inc. issued a press release announcingits financial results for the three months ended March 31, 2022.... | May 4, 2022